WO2002030458A8 - Yersinia adhesion protein as vaccine adjuvant - Google Patents

Yersinia adhesion protein as vaccine adjuvant

Info

Publication number
WO2002030458A8
WO2002030458A8 PCT/EP2001/003786 EP0103786W WO0230458A8 WO 2002030458 A8 WO2002030458 A8 WO 2002030458A8 EP 0103786 W EP0103786 W EP 0103786W WO 0230458 A8 WO0230458 A8 WO 0230458A8
Authority
WO
WIPO (PCT)
Prior art keywords
present
yersinia
adhesion protein
vaccines
vaccine adjuvant
Prior art date
Application number
PCT/EP2001/003786
Other languages
French (fr)
Other versions
WO2002030458A1 (en
Inventor
Philippe Hermand
Velde Vincent Vande
Original Assignee
Smithkline Beecham Biolog
Philippe Hermand
Velde Vincent Vande
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog, Philippe Hermand, Velde Vincent Vande filed Critical Smithkline Beecham Biolog
Priority to AU2001262163A priority Critical patent/AU2001262163A1/en
Publication of WO2002030458A1 publication Critical patent/WO2002030458A1/en
Publication of WO2002030458A8 publication Critical patent/WO2002030458A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a Yersinia adhesion protein, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.
PCT/EP2001/003786 2000-10-12 2001-03-26 Yersinia adhesion protein as vaccine adjuvant WO2002030458A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001262163A AU2001262163A1 (en) 2000-10-12 2001-03-26 Composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0025058.9A GB0025058D0 (en) 2000-10-12 2000-10-12 Composition
GB0025058.9 2000-10-12

Publications (2)

Publication Number Publication Date
WO2002030458A1 WO2002030458A1 (en) 2002-04-18
WO2002030458A8 true WO2002030458A8 (en) 2002-07-18

Family

ID=9901176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003786 WO2002030458A1 (en) 2000-10-12 2001-03-26 Yersinia adhesion protein as vaccine adjuvant

Country Status (5)

Country Link
AR (1) AR027738A1 (en)
AU (1) AU2001262163A1 (en)
CO (1) CO5270014A1 (en)
GB (1) GB0025058D0 (en)
WO (1) WO2002030458A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854803B1 (en) * 2003-05-16 2005-06-24 Aventis Pasteur VACCINE COMPOSITION COMPRISING IRON PHOSPHATE AS VACCINE.
JP2010502747A (en) * 2006-09-08 2010-01-28 ベクトン・ディキンソン・アンド・カンパニー A stable powder formulation of alum-adsorbed vaccine
EP2034022A1 (en) 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
EP2045263A1 (en) 2007-10-02 2009-04-08 Universite Libre De Bruxelles Identification and molecular characterisation of salivary metalloproteases expressed in the tick salivary glands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239066A (en) * 1985-07-31 1993-08-24 The Board Of Trustees Of Leland Stanford Jr. University Yersinia ail nucleic acids
US5338842A (en) * 1985-07-31 1994-08-16 The Board Of Trustees Of Leland Stanford Jr. University Yersinia INV nucleic acids
EP1198245B1 (en) * 1998-09-30 2004-08-25 Walter Reed Army Institute of Research Use of purified invaplex from gram negative bacteria as a vaccine
ATE290012T1 (en) * 1998-10-21 2005-03-15 Univ Kansas Ct For Res Inc METHOD FOR PRODUCING PURIFIED INVASIN PROTEIN AND ITS APPLICATION

Also Published As

Publication number Publication date
GB0025058D0 (en) 2000-11-29
CO5270014A1 (en) 2003-04-30
AU2001262163A1 (en) 2002-04-22
AR027738A1 (en) 2003-04-09
WO2002030458A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2002080965A3 (en) Vaccine composition
GB0025577D0 (en) Vaccine
WO2006085983A3 (en) Viral adjuvants
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
WO2006040076A3 (en) Vaccination adjuvants pam3cys, poly(i:c), imiquimod, loxoribine, r-848 and cpg-dna together with mhc i or mhc ii epitopes
WO2003028760A3 (en) Vaccine
WO2002087494A3 (en) Novel vaccine
WO2003059385A3 (en) Hiv vaccine and method of use
WO2003066094A3 (en) Hepatitis b vaccines
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2006004390A3 (en) Preparation and use of a bivalent vaccine against morphine-heroin addiction
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
MY127452A (en) Vaccines.
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
WO2005048918A3 (en) Anthrax vaccine
WO2006064378A3 (en) Adjuvant activity of gastrointestinal peptides
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
WO2002036160A3 (en) Method for obtaining antigenic structures enhancing specific cross reactivity
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
WO2002070004A3 (en) Papillomavirus vaccines
WO2004013166A3 (en) S. aureus antigene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP